Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Autoimmune Disorders

  Free Subscription


30.04.2018

1 Curr Treat Options Neurol
1 J Autoimmun
6 J Neuroimmunol
2 J Neurol
1 Kidney Int
14 Lancet Diabetes Endocrinol
2 Lancet Neurol
7 Mult Scler
5 Neurology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Curr Treat Options Neurol

  1. JOKUBAITIS VG, Zhou Y, Butzkueven H, Taylor BV, et al
    Genotype and Phenotype in Multiple Sclerosis-Potential for Disease Course Prediction?
    Curr Treat Options Neurol. 2018;20:18.
    PubMed     Text format     Abstract available


    J Autoimmun

  2. GHRAIEB A, Keren A, Ginzburg A, Ullmann Y, et al
    iNKT cells ameliorate human autoimmunity: Lessons from alopecia areata.
    J Autoimmun. 2018 Apr 18. pii: S0896-8411(17)30541.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  3. SERIZAWA K, Tomizawa-Shinohara H, Magi M, Yogo K, et al
    Anti-IL-6 receptor antibody improves pain symptoms in mice with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;319:71-79.
    PubMed     Text format     Abstract available

  4. SERAFINI B, Zandee S, Rosicarelli B, Scorsi E, et al
    Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption.
    J Neuroimmunol. 2018;319:9-12.
    PubMed     Text format    

  5. TIJERO B, Del Pino R, Perez-Concha T, Acera MA, et al
    Seronegative and seropositive autoimmune autonomic ganglionopathy (AAG): Same clinical picture, same response to immunotherapy.
    J Neuroimmunol. 2018;319:68-70.
    PubMed     Text format     Abstract available

  6. YOSHIKURA N, Kimura A, Fukata M, Fukata Y, et al
    Long-term clinical follow-up of a patient with non-paraneoplastic cerebellar ataxia associated with anti-mGluR1 autoantibodies.
    J Neuroimmunol. 2018;319:63-67.
    PubMed     Text format     Abstract available

  7. HIRATSUKA D, Furube E, Taguchi K, Tanaka M, et al
    Remyelination in the medulla oblongata of adult mouse brain during experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;319:41-54.
    PubMed     Text format     Abstract available

  8. AKAISHI T, Takahashi T, Nakashima I
    Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis.
    J Neuroimmunol. 2018;319:37-40.
    PubMed     Text format     Abstract available


    J Neurol

  9. RASUL T, Frederiksen JL
    Link between overweight/obese in children and youngsters and occurrence of multiple sclerosis.
    J Neurol. 2018 Apr 26. pii: 10.1007/s00415-018-8869.
    PubMed     Text format     Abstract available

  10. HUHN K, Bayas A, Doerck S, Frank B, et al
    Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    J Neurol. 2018 Apr 25. pii: 10.1007/s00415-018-8871.
    PubMed     Text format     Abstract available


    Kidney Int

  11. LIM CC, Choo JCJ, Chan CM, Woo KT, et al
    Age-adjusted global glomerulosclerosis in addition to Oxford histological classification of IgA nephropathy.
    Kidney Int. 2018;93:1250.
    PubMed     Text format    


    Lancet Diabetes Endocrinol

  12. THOMAS NJ, Jones SE, Weedon MN, Shields BM, et al
    Genetic risk scores in adult-onset type 1 diabetes - Authors' reply.
    Lancet Diabetes Endocrinol. 2018;6:169.
    PubMed     Text format    

  13. TEN KATE Q, Aanstoot HJ, Birnie E, Veeze H, et al
    GADA persistence and diabetes classification.
    Lancet Diabetes Endocrinol. 2016;4:563-4.
    PubMed     Text format    

  14. NASIR H, Narasimhan S
    Type 1 diabetes: the need for culture-appropriate nutritional information for carbohydrate counting.
    Lancet Diabetes Endocrinol. 2016 Jul 25. pii: S2213-8587(16)30101.
    PubMed     Text format    

  15. LESLIE RD, Lernmark A
    Genetic risk scores in adult-onset type 1 diabetes.
    Lancet Diabetes Endocrinol. 2018;6:168-169.
    PubMed     Text format    

  16. LIND M, Rosengren A
    Atrial fibrillation and type 1 diabetes - Authors' reply.
    Lancet Diabetes Endocrinol. 2017;5:937.
    PubMed     Text format    

  17. XIAO Y, Sun L
    Atrial fibrillation and type 1 diabetes.
    Lancet Diabetes Endocrinol. 2017;5:936-937.
    PubMed     Text format    

  18. LI Q, An Z, Tian H, Li S, et al
    Atrial fibrillation and type 1 diabetes.
    Lancet Diabetes Endocrinol. 2017;5:936.
    PubMed     Text format    

  19. HYGUM K, Langdahl BL, Starup-Linde J
    Disentangling the association between diabetes and bone disease.
    Lancet Diabetes Endocrinol. 2017;5:769.
    PubMed     Text format    

  20. PETRIE JR
    SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?
    Lancet Diabetes Endocrinol. 2017 Sep 13. pii: S2213-8587(17)30315.
    PubMed     Text format    

  21. STANDL E
    Metformin in type 1 diabetes.
    Lancet Diabetes Endocrinol. 2017 Jun 9. pii: S2213-8587(17)30216.
    PubMed     Text format    

  22. RIDDELL MC, Gallen IW, Rabasa-Lhoret R
    Exercise and physical activity in patients with type 1 diabetes - Authors' reply.
    Lancet Diabetes Endocrinol. 2017 May 19. pii: S2213-8587(17)30168.
    PubMed     Text format    

  23. CAMPBELL MD, Kime N, McKenna J
    Exercise and physical activity in patients with type 1 diabetes.
    Lancet Diabetes Endocrinol. 2017 May 19. pii: S2213-8587(17)30169.
    PubMed     Text format    

  24. POUWER F
    Fatigue in type 1 diabetes: an understudied problem.
    Lancet Diabetes Endocrinol. 2017 Apr 24. pii: S2213-8587(17)30137.
    PubMed     Text format    

  25. EL YOUSSEF J
    IN CONTROL of type 1 diabetes, despite hypoglycaemia unawareness.
    Lancet Diabetes Endocrinol. 2016 Sep 14. pii: S2213-8587(16)30261.
    PubMed     Text format    


    Lancet Neurol

  26. MISAWA S, Kuwabara S, Sato Y, Yamaguchi N, et al
    Safety and efficacy of eculizumab in Guillain-Barre syndrome: a multicentre, double-blind, randomised phase 2 trial.
    Lancet Neurol. 2018 Apr 20. pii: S1474-4422(18)30114.
    PubMed     Text format     Abstract available

  27. NOBILE-ORAZIO E
    The complement story in Guillain-Barre syndrome: from pathogenesis to therapy.
    Lancet Neurol. 2018 Apr 20. pii: S1474-4422(18)30144.
    PubMed     Text format    


    Mult Scler

  28. WAGLEY S, Bokori-Brown M, Morcrette H, Malaspina A, et al
    Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518767327. doi: 10.1177/1352458518767327.
    PubMed     Text format     Abstract available

  29. MCCLURG D, Bugge C, Elders A, Irshad T, et al
    Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: Results of the COSMOS mixed-methods study.
    Mult Scler. 2018 Apr 1:1352458518768722. doi: 10.1177/1352458518768722.
    PubMed     Text format     Abstract available

  30. CREARY LE, Mallempati KC, Gangavarapu S, Caillier SJ, et al
    Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770019. doi: 10.1177/1352458518770019.
    PubMed     Text format     Abstract available

  31. LLUFRIU S, Rocca MA, Pagani E, Riccitelli GC, et al
    Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis.
    Mult Scler. 2018 Apr 1:1352458518771838. doi: 10.1177/1352458518771838.
    PubMed     Text format     Abstract available

  32. SAUL A, Taylor B, Simpson S Jr, Ponsonby AL, et al
    Polymorphism in the serotonin transporter gene polymorphisms ( 5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770021. doi: 10.1177/1352458518770021.
    PubMed     Text format     Abstract available

  33. LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
    Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768433. doi: 10.1177/1352458518768433.
    PubMed     Text format     Abstract available

  34. MARRIE RA, Montalban X
    Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.
    Mult Scler. 2018;24:558-562.
    PubMed     Text format    


    Neurology

  35. GERARDI C, Bertele' V, Rossi S, Garattini S, et al
    Preapproval and postapproval evidence on drugs for multiple sclerosis.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005561.
    PubMed     Text format     Abstract available

  36. BAR-OR A, Grove RA, Austin DJ, Tolson JM, et al
    Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005516.
    PubMed     Text format     Abstract available

  37. COBO-CALVO A, Ruiz A, Maillart E, Audoin B, et al
    Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005560.
    PubMed     Text format     Abstract available

  38. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:789-800.
    PubMed     Text format     Abstract available

  39. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:777-788.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: